NASDAQ:TFFP TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free TFFP Stock Alerts $2.97 -0.04 (-1.33%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$2.97▼$2.9750-Day Range$2.58▼$8.9952-Week Range$2.51▼$21.25Volume210 shsAverage Volume28,013 shsMarket Capitalization$7.48 millionP/E RatioN/ADividend YieldN/APrice Target$72.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TFF Pharmaceuticals alerts: Email Address TFF Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,324.2% Upside$72.00 Price TargetShort InterestHealthy2.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($7.28) to ($7.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.81 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTFF Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.77% of the float of TFF Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTFF Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TFF Pharmaceuticals has recently decreased by 19.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTFF Pharmaceuticals does not currently pay a dividend.Dividend GrowthTFF Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TFFP. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for TFFP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added TFF Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of TFF Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 15.25% of the stock of TFF Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TFF Pharmaceuticals are expected to decrease in the coming year, from ($7.28) to ($7.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TFF Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TFF Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTFF Pharmaceuticals has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About TFF Pharmaceuticals Stock (NASDAQ:TFFP)TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.Read More TFFP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TFFP Stock News HeadlinesApril 17, 2024 | msn.comTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99April 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation PowderApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 15, 2024 | globenewswire.comTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract SessionsApril 1, 2024 | finance.yahoo.comTFF Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 29, 2024 | investing.comTFF Pharmaceuticals reports positive phase 2 trial resultsMarch 29, 2024 | finanznachrichten.deTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | investorplace.comTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023April 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 28, 2024 | globenewswire.comTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | globenewswire.comTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical ProgramsMarch 25, 2024 | globenewswire.comTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingMarch 22, 2024 | globenewswire.comTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 21, 2024 | finance.yahoo.comTFF Pharmaceuticals, Inc. (TFFP)March 20, 2024 | globenewswire.comTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 20, 2024 | globenewswire.comTFF Pharmaceuticals Announces Update on Clinical ProgramsMarch 14, 2024 | globenewswire.comTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024March 12, 2024 | uk.investing.comTff Pharmaceuticals Inc (TFFP)January 24, 2024 | finance.yahoo.comTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis ConferenceJanuary 9, 2024 | finance.yahoo.comTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingJanuary 5, 2024 | morningstar.comTFF Pharmaceuticals Inc Ordinary SharesDecember 21, 2023 | markets.businessinsider.comPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price TargetDecember 19, 2023 | finanznachrichten.deTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACDecember 19, 2023 | markets.businessinsider.comTFF Pharma Reveals Positive Initial Data From Ongoing Phase 2 Trials Of TFF VORI And TFF TACDecember 19, 2023 | finance.yahoo.comTFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACDecember 18, 2023 | finance.yahoo.comTFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TACDecember 15, 2023 | markets.businessinsider.comTFF Declares Reverse Stock Split For 1 Post-split Share For Every 25 Pre-split SharesSee More Headlines Receive TFFP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TFFP CUSIPN/A CIK1733413 Webwww.tffpharma.com Phone817-438-6168FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$72.00 High Stock Price Target$100.00 Low Stock Price Target$44.00 Potential Upside/Downside+2,292.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,240,000.00 Net Margins-2,897.95% Pretax Margin-2,894.14% Return on Equity-163.14% Return on Assets-144.77% Debt Debt-to-Equity RatioN/A Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual Sales$730,000.00 Price / Sales10.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.75Miscellaneous Outstanding Shares2,520,000Free Float2,378,000Market Cap$7.59 million OptionableOptionable Beta1.29 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Harlan F. Weisman (Age 72)President, CEO & Director Comp: $594.48kMr. Kirk Allen Coleman (Age 50)CFO, Treasurer & Secretary Comp: $382.22kDr. Zamaneh Mikhak M.D. (Age 60)Chief Medical Officer Key CompetitorsBiofronteraNASDAQ:BFRIASLAN PharmaceuticalsNASDAQ:ASLNBionomicsNASDAQ:BNOXLixte BiotechnologyNASDAQ:LIXTChemomab TherapeuticsNASDAQ:CMMBView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Bought 31,089 shares on 4/19/2024Ownership: 1.557%AIGH Capital Management LLCSold 2,625,753 shares on 2/12/2024Ownership: 1.247%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Carlson Capital L PSold 8,600 sharesTotal: $94,600.00 ($11.00/share)Harlan F WeismanBought 24,000 shares on 8/15/2023Total: $150,000.00 ($6.25/share)View All Insider TransactionsView All Institutional Transactions TFFP Stock Analysis - Frequently Asked Questions Should I buy or sell TFF Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TFFP shares. View TFFP analyst ratings or view top-rated stocks. What is TFF Pharmaceuticals' stock price target for 2024? 1 brokers have issued twelve-month price targets for TFF Pharmaceuticals' shares. Their TFFP share price targets range from $44.00 to $100.00. On average, they expect the company's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 2,324.2% from the stock's current price. View analysts price targets for TFFP or view top-rated stocks among Wall Street analysts. How have TFFP shares performed in 2024? TFF Pharmaceuticals' stock was trading at $7.02 at the beginning of the year. Since then, TFFP shares have decreased by 57.7% and is now trading at $2.97. View the best growth stocks for 2024 here. Are investors shorting TFF Pharmaceuticals? TFF Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 86,600 shares, an increase of 86.6% from the March 15th total of 46,400 shares. Based on an average trading volume of 28,500 shares, the short-interest ratio is currently 3.0 days. Currently, 3.4% of the shares of the stock are sold short. View TFF Pharmaceuticals' Short Interest. When is TFF Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TFFP earnings forecast. How were TFF Pharmaceuticals' earnings last quarter? TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced its earnings results on Thursday, March, 28th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($2.00) by $0.01. The firm earned $0.11 million during the quarter, compared to analysts' expectations of $0.20 million. TFF Pharmaceuticals had a negative trailing twelve-month return on equity of 163.14% and a negative net margin of 2,897.95%. When did TFF Pharmaceuticals' stock split? TFF Pharmaceuticals shares reverse split before market open on Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of TFF Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX). When did TFF Pharmaceuticals IPO? TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO. Who are TFF Pharmaceuticals' major shareholders? TFF Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Westside Investment Management Inc. (1.56%). Insiders that own company stock include Aaron GL Fletcher, Carlson Capital L P, Glenn R Mattes, Harlan F Weisman, Kirk Allen Coleman, Malcolm Fairbairn, Randy H Thurman, Stephen Rocamboli and Zamaneh Mikhak. View institutional ownership trends. How do I buy shares of TFF Pharmaceuticals? Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TFFP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TFF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
